Diagnosis, Initial Management, and Prevention of Meningitis

Am Fam Physician. 2010 Dec 15;82(12):1491-1498.

  Patient Information: See related handout on the pneumococcal conjugate vaccine.

Although the annual incidence of bacterial meningitis in the United States is declining, it remains a medical emergency with a potential for high morbidity and mortality. Clinical signs and symptoms are unreliable in distinguishing bacterial meningitis from the more common forms of aseptic meningitis; therefore, a lumbar puncture with cerebrospinal fluid analysis is recommended. Empiric antimicrobial therapy based on age and risk factors must be started promptly in patients with bacterial meningitis. Empiric therapy should not be delayed, even if a lumbar puncture cannot be performed because results of a computed tomography scan are pending or because the patient is awaiting transfer. Concomitant therapy with dexamethasone initiated before or at the time of antimicrobial therapy has been demonstrated to improve morbidity and mortality in adults with Streptococcus pneumoniae infection. Within the United States, almost 30 percent of strains of pneumococci, the most common etiologic agent of bacterial meningitis, are not susceptible to penicillin. Among adults in developed countries, the mortality rate from bacterial meningitis is 21 percent. However, the use of conjugate vaccines has reduced the incidence of bacterial meningitis in children and adults.

Acute meningitis is a medical emergency with a potential for high morbidity and mortality. Bacterial meningitis is life threatening, and must be distinguished from the more common aseptic (viral) meningitis. With increased use of conjugate vaccines, the annual incidence of bacterial meningitis in the United States declined from 1.9 to 1.5 cases per 100,000 persons between 1998 and 2003, with an overall mortality rate of 15.6 percent.13 Incidence rates in developing countries remain significantly higher.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Evaluation of cerebrospinal fluid is key to the diagnosis of meningitis. Decision rules using clinical and laboratory findings are highly sensitive in diagnosing meningitis in children.

C

5, 8, 13, 21

Patients with risk factors for occult intracranial abnormalities should undergo computed tomography of the brain before lumbar puncture.

C

17

If bacterial meningitis is suspected, empiric therapy with antimicrobials should not be delayed for more than one hour in patients awaiting diagnostic testing or transfers.

C

4, 18, 22, 23

Adults with Streptococcus pneumoniae or Mycobacterium tuberculosis infection should receive concomitant dexamethasone with antimicrobial therapy to reduce mortality and improve neurologic outcomes.

B

19, 25, 32

Conjugate vaccines for S. pneumoniae and Haemophilus influenzae type B are recommended for patients in appropriate risk groups to reduce the incidence of bacterial meningitis.

B

1, 2


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Evaluation of cerebrospinal fluid is key to the diagnosis of meningitis. Decision rules using clinical and laboratory findings are highly sensitive in diagnosing meningitis in children.

C

5, 8, 13, 21

Patients with risk factors for occult intracranial abnormalities should undergo computed tomography of the brain before lumbar puncture.

C

17

If bacterial meningitis is suspected, empiric therapy with antimicrobials should not be delayed for more than one hour in patients awaiting diagnostic testing or transfers.

C

4, 18, 22, 23

Adults with Streptococcus pneumoniae or Mycobacterium tuberculosis infection should receive concomitant dexamethasone with antimicrobial therapy to reduce mortality and improve neurologic outcomes.

B

19, 25, 32

Conjugate vaccines for S. pneumoniae and Haemophilus influenzae type B are recommended for patients in appropriate risk groups to reduce the incidence of bacterial meningitis.

B

1, 2


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Etiology

Age, immunosuppression, and neurosurgical procedures increase the likelihood of infection from specific pathogens (Table 1).3,4 In persons with community-acquired meningitis, aseptic meningitis is significantly more common than bacterial meningitis; 96 percent of children with cerebrospinal fluid (CSF) pleocytosis have aseptic meningitis.5 The most common etiologies of aseptic meningitis are enterovirus, herpes simplex virus (HSV), and Borrelia burgdorferi infections. In adults, the incidence of aseptic meningitis is 7.6 cases per 100,000 persons, and the most common etiologies are enterovirus, HSV, and varicella-zoster virus infections.6 Other pathogens and diseases associated with aseptic meningitis include Treponema pallidum, Mycoplasma pneumoniae, Rocky Mountain spotted fever, ehrlichiosis, mumps, lymphocytic choriomeningitis virus, and acute retroviral syndrome associated with human immunodeficiency virus (HIV) infection.

Table 1.

Common Etiologies of Bacterial Meningitis and Recommended Empiric Therapy*

Population Likely pathogen Empiric therapy

Infants younger than one month

Streptococcus agalactiae (group B streptococcus), Listeria monocytogenes, Escherichia coli, other gram-negative bacilli

Ampicillin and cefotaxime (Claforan)

Children one to 23 months of age

Streptococcus pneumoniae, Neisseria meningitidis, S. agalactiae, Haemophilus influenzae, E. coli

Vancomycin and ceftriaxone (Rocephin)

Children and adults two to 50 years of age

N. meningitidis, S. pneumoniae

Vancomycin and ceftriaxone

Adults older than 50 years, with altered cellular immunity, or with alcoholism

S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic gram-negative bacilli

Vancomycin, ceftriaxone, and ampicillin

Patients with basilar skull fracture or cochlear implant

S. pneumoniae, H. influenzae, group A beta-hemolytic streptococci

Vancomycin and ceftriaxone

Patients with penetrating trauma or postneurosurgery

Staphylococcus aureus, coagulase-negative staphylococci, aerobic gram-negative bacilli (including Pseudomonas aeruginosa)

Vancomycin and cefepime (Maxipime)

Patients with cerebrospinal fluid shunt

Coagulase-negative staphylococci, S. aureus, aerobic gram-negative bacilli (including P. aeruginosa), Propionibacterium acnes

Vancomycin and cefepime


* —In 2002–2003 among all age groups in the United States, 61 percent of bacterial meningitis was caused by S. pneumoniae, 16 percent by N. meningitidis, 14 percent by S. agalactiae (group B streptococcus), 7 percent by H. influenzae, and 2 percent by L. monocytogenes.3

Adapted with permission from Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1275, with additional information from reference 3.

Table 1.   Common Etiologies of Bacterial Meningitis and Recommended Empiric Therapy*

View Table

Table 1.

Common Etiologies of Bacterial Meningitis and Recommended Empiric Therapy*

Population Likely pathogen Empiric therapy

Infants younger than one month

Streptococcus agalactiae (group B streptococcus), Listeria monocytogenes, Escherichia coli, other gram-negative bacilli

Ampicillin and cefotaxime (Claforan)

Children one to 23 months of age

Streptococcus pneumoniae, Neisseria meningitidis, S. agalactiae, Haemophilus influenzae, E. coli

Vancomycin and ceftriaxone (Rocephin)

Children and adults two to 50 years of age

N. meningitidis, S. pneumoniae

Vancomycin and ceftriaxone

Adults older than 50 years, with altered cellular immunity, or with alcoholism

S. pneumoniae, N. meningitidis, L. monocytogenes, aerobic gram-negative bacilli

Vancomycin, ceftriaxone, and ampicillin

Patients with basilar skull fracture or cochlear implant

S. pneumoniae, H. influenzae, group A beta-hemolytic streptococci

Vancomycin and ceftriaxone

Patients with penetrating trauma or postneurosurgery

Staphylococcus aureus, coagulase-negative staphylococci, aerobic gram-negative bacilli (including Pseudomonas aeruginosa)

Vancomycin and cefepime (Maxipime)

Patients with cerebrospinal fluid shunt

Coagulase-negative staphylococci, S. aureus, aerobic gram-negative bacilli (including P. aeruginosa), Propionibacterium acnes

Vancomycin and cefepime


* —In 2002–2003 among all age groups in the United States, 61 percent of bacterial meningitis was caused by S. pneumoniae, 16 percent by N. meningitidis, 14 percent by S. agalactiae (group B streptococcus), 7 percent by H. influenzae, and 2 percent by L. monocytogenes.3

Adapted with permission from Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1275, with additional information from reference 3.

Patients with mosquito-borne arboviral infections (e.g., West Nile virus, St. Louis encephalitis, the California encephalitis group) often present with encephalitis; however, they may present with meningeal involvement alone and no neurologic manifestations. Seasonality is important in predicting the likelihood of aseptic meningitis, because most enteroviral and arboviral infections occur in the summer or fall in temperate climates. Tuberculous and fungal meningitis are less common in the United States, and usually produce more chronic symptoms. Cryptococcal meningitis is common in patients with altered cellular immunity, especially in those with advanced HIV infection (e.g., CD4 cell count of less than 200 cells per mm3 [200 × 109 per L]).

Clinical Presentation

In adults with community-acquired bacterial meningitis, 25 percent have recent otitis or sinusitis, 12 percent have pneumonia, and16 percent are immunocompromised.7  Typical clinical features are listed in Table 2.7 At least one of the cardinal features of fever, neck stiffness, and altered mental status is present in 99 to 100 percent of patients with meningitis; when headache is included, two of the four features are observed in 95 percent of patients with meningitis.7,8 The Kernig and Brudzinski signs are poorly sensitive but highly specific for bacterial meningitis.9 Sixty-three percent of patients with meningococcal meningitis present with a rash that is usually petechial.7 Petechial rash may also be caused by Haemophilus influenzae or Streptococcus pneumoniae infection. Pneumococcal meningitis is more likely than meningococcal meningitis to be associated with seizures, focal neurologic findings, and altered consciousness.

Table 2.

Clinical and Laboratory Findings in Adults with Bacterial Meningitis

Clinical or laboratory feature Sensitivity (%)

Two of the following features: fever, neck stiffness, altered mental status, and headache

95

Cerebrospinal fluid white blood cell count ≥ 100 per μL (0.10 × 109 per L)

93

Headache

87

Neck stiffness

83

Fever ≥ 100.4°F (38°C)

77

Nausea

74

Altered mental status (Glasgow Coma Scale score < 14)

69

Growth of organism in blood culture

66

Triad of fever, neck stiffness, and altered mental status

44

Focal neurologic signs

33

Seizure

5

Papilledema

3


Information from reference 7.

Table 2.   Clinical and Laboratory Findings in Adults with Bacterial Meningitis

View Table

Table 2.

Clinical and Laboratory Findings in Adults with Bacterial Meningitis

Clinical or laboratory feature Sensitivity (%)

Two of the following features: fever, neck stiffness, altered mental status, and headache

95

Cerebrospinal fluid white blood cell count ≥ 100 per μL (0.10 × 109 per L)

93

Headache

87

Neck stiffness

83

Fever ≥ 100.4°F (38°C)

77

Nausea

74

Altered mental status (Glasgow Coma Scale score < 14)

69

Growth of organism in blood culture

66

Triad of fever, neck stiffness, and altered mental status

44

Focal neurologic signs

33

Seizure

5

Papilledema

3


Information from reference 7.

Compared with younger adults, persons 65 years and older with bacterial meningitis are less likely to have headache, nausea, vomiting, and nuchal rigidity, and are more likely to have seizures and hemiparesis.10 Similarly, the classical features of bacterial meningitis are not observed as often in younger children, who may present with subtle findings, such as lethargy and irritability.11 A recent history of upper respiratory tract infection is common in children with bacterial meningitis; children are also more likely than adults to experience a seizure. 12 The illness course varies, with progression over hours to several days. The clinical features are nonspecific. For example, in a study of 297 adults who underwent a lumbar puncture for suspected meningitis, only 80 (27 percent) had any degree of CSF pleocytosis, only 20 (6.7 percent) had a white blood cell count of 100 cells per μL [0.10 × 109 per L] or higher, and only three (1 percent) had culture-confirmed bacterial meningitis.9

Initial Evaluation

Given the lack of specificity of clinical findings, the key to the diagnosis of meningitis is the evaluation of CSF.13 The peripheral white blood cell count alone is not helpful in distinguishing bacterial from aseptic meningitis, particularly in young children (i.e., a normal white blood cell count does not rule out bacterial meningitis).14 Meningitis should be suspected in patients with those features previously noted that cannot be fully explained by other diagnoses. Lumbar puncture is a safe procedure, although postprocedure headache occurs in about one third of patients.15 (A video of a lumbar puncture is available at http://content.nejm.org/cgi/content/short/355/13/e12.) The concern with lumbar puncture is the poorly quantified risk of herniation in patients with a space-occupying lesion or severe diffuse cerebral swelling, and the degree to which the risk can be recognized by a previous computed tomography scan. Life-threatening herniation from lumbar puncture has not been reported in patients who are neurologically unremarkable before the procedure.16

Based on patient series17 and guidelines,4,18 patients with risk factors for occult intracranial abnormalities should undergo computed tomography of the brain before lumbar puncture. This includes patients with central nervous system disease (including CSF shunts, hydrocephalus, trauma, space-occupying lesions or recent neurosurgery, immunocompromised state, papilledema, focal neurologic signs) and adults with new-onset seizures or moderately to severely impaired consciousness (Figure 14,1618). During the initial evaluation of a patient with suspected meningitis, diagnostic and therapeutic maneuvers should begin concomitantly. If a computed tomography scan is required before a lumbar puncture, blood cultures should be obtained, followed by prompt initiation of empiric antimicrobial therapy before the scan. Adjunctive therapy with dexamethasone should be added in adults with suspected S. pneumoniae infection.19

Initial Management of Suspected Acute Meningitis

Figure 1.

Algorithm for the initial management of suspected acute meningitis. (CSF = cerebrospinal fluid.)

Information from references 4, and 16 through 18.

View Large

Initial Management of Suspected Acute Meningitis


Figure 1.

Algorithm for the initial management of suspected acute meningitis. (CSF = cerebrospinal fluid.)

Information from references 4, and 16 through 18.

Initial Management of Suspected Acute Meningitis


Figure 1.

Algorithm for the initial management of suspected acute meningitis. (CSF = cerebrospinal fluid.)

Information from references 4, and 16 through 18.

After CSF is obtained, the Gram stain results, white and red blood cell counts, glucose levels, and protein levels should be evaluated immediately. Although no single measure is diagnostic, a combination of abnormal CSF findings is highly suggestive of meningitis and helpful in determining the likely etiology (Table 3). Rarely, patients with bacterial meningitis may present with normal or near-normal white blood cell counts, glucose levels, and protein levels. This has been observed in young children with neutropenia and other immunocompromised states, and very early in the course of meningococcal meningitis.20 Lack of CSF leukocytosis and normal CSF glucose levels are also common in patients with HIV infection and cryptococcal meningitis, but the CSF cryptococcal antigen test is highly sensitive and specific. Patients with partially treated bacterial meningitis and those with Listeria infection may have a CSF profile that is similar to aseptic meningitis. In children who have not received previous antimicrobial agents, clinical decision rules are useful in identifying those at low risk of bacterial meningitis and, if otherwise clinically stable, who are eligible for careful observation without antimicrobial therapy (Table 4).5,21

Table 3.

Typical CSF Parameters in Patients with Meningitis

Pathogen White blood cells per μL (× 109 per L) Percentage of neutrophils Glucose level Protein level in mg per dL (g per L) Likelihood of observing organism on CSF stain

Pyogenic (not Listeria monocytogenes)

> 500 (0.50)

> 80

Low

> 100 (1.00)

~70 percent

L. monocytogenes

> 100 (0.10)

~50

Normal

> 50 (0.50)

~30 percent

Partially treated pyogenic

> 100

~50

Normal

> 70 (0.70)

~60 percent

Aseptic, often viral

10 to 1,000 (0.01 to 1.00)

Early: > 50 Late: < 20

Normal

< 200 (2.00)

Not applicable

Tubercular

50 (0.05) to 500

< 30

Low

> 100

Rare

Fungal

50 to 500

< 30

Low

Varies

Often high in cryptococcus


CSF = cerebrospinal fluid.

Table 3.   Typical CSF Parameters in Patients with Meningitis

View Table

Table 3.

Typical CSF Parameters in Patients with Meningitis

Pathogen White blood cells per μL (× 109 per L) Percentage of neutrophils Glucose level Protein level in mg per dL (g per L) Likelihood of observing organism on CSF stain

Pyogenic (not Listeria monocytogenes)

> 500 (0.50)

> 80

Low

> 100 (1.00)

~70 percent

L. monocytogenes

> 100 (0.10)

~50

Normal

> 50 (0.50)

~30 percent

Partially treated pyogenic

> 100

~50

Normal

> 70 (0.70)

~60 percent

Aseptic, often viral

10 to 1,000 (0.01 to 1.00)

Early: > 50 Late: < 20

Normal

< 200 (2.00)

Not applicable

Tubercular

50 (0.05) to 500

< 30

Low

> 100

Rare

Fungal

50 to 500

< 30

Low

Varies

Often high in cryptococcus


CSF = cerebrospinal fluid.

Table 4.

Clinical Decision Rules to Distinguish Bacterial from Aseptic Meningitis in Children with CSF Pleocytosis*

Rule Bacterial Meningitis Score 5 Meningitest 21

Exclusion criteria

Neurosurgical history Immunosuppression CSF red blood cell count ≥ 0.01 × 106 per μL (0.01 × 1012 per L) Antibiotic use in the previous 48 hours Purpura

Neurosurgical history Immunosuppression CSF red blood cell count ≥ 0.01 × 106 per μL Antibiotic use in the previous 48 hours

Criteria (further evaluation, including lumbar puncture, is needed in patients with one or more findings)

Positive CSF Gram stain

Positive CSF Gram stain

Seizure

Seizure

Blood neutrophil count ≥ 10,000 per μL (10.00 × 109 per L)

Purpura

Toxic appearance (irritability, lethargy, or low capillary refill)

CSF neutrophil count ≥ 1,000 per μL (1.00 x 109 per L)

CSF protein level ≥ 50 mg per dL (0.50 g per L)

CSF protein level ≥ 80 mg per dL (0.80 g per L)

Serum procalcitonin level ≥ 0.5 ng per mL

Sensitivity (95% confidence interval)

99 percent (99 to 100)

100 percent (96 to 100)


CSF = cerebrospinal fluid.

*—White blood cell count ≥ 10 per μL (0.01 × 109 per L).

Adapted with permission from Dubos F, Martinot A, Gendrel D, Bréart G, Chalumeau M. Clinical decision rules for evaluating meningitis in children. Curr Opin Neurol. 2009;22(3):292, with additional information from reference 5.

Table 4.   Clinical Decision Rules to Distinguish Bacterial from Aseptic Meningitis in Children with CSF Pleocytosis*

View Table

Table 4.

Clinical Decision Rules to Distinguish Bacterial from Aseptic Meningitis in Children with CSF Pleocytosis*

Rule Bacterial Meningitis Score 5 Meningitest 21

Exclusion criteria

Neurosurgical history Immunosuppression CSF red blood cell count ≥ 0.01 × 106 per μL (0.01 × 1012 per L) Antibiotic use in the previous 48 hours Purpura

Neurosurgical history Immunosuppression CSF red blood cell count ≥ 0.01 × 106 per μL Antibiotic use in the previous 48 hours

Criteria (further evaluation, including lumbar puncture, is needed in patients with one or more findings)

Positive CSF Gram stain

Positive CSF Gram stain

Seizure

Seizure

Blood neutrophil count ≥ 10,000 per μL (10.00 × 109 per L)

Purpura

Toxic appearance (irritability, lethargy, or low capillary refill)

CSF neutrophil count ≥ 1,000 per μL (1.00 x 109 per L)

CSF protein level ≥ 50 mg per dL (0.50 g per L)

CSF protein level ≥ 80 mg per dL (0.80 g per L)

Serum procalcitonin level ≥ 0.5 ng per mL

Sensitivity (95% confidence interval)

99 percent (99 to 100)

100 percent (96 to 100)


CSF = cerebrospinal fluid.

*—White blood cell count ≥ 10 per μL (0.01 × 109 per L).

Adapted with permission from Dubos F, Martinot A, Gendrel D, Bréart G, Chalumeau M. Clinical decision rules for evaluating meningitis in children. Curr Opin Neurol. 2009;22(3):292, with additional information from reference 5.

Bacterial Meningitis

Initial empiric therapy of bacterial meningitis is based on the patient's age, risk factors, and clinical features (Table 1).3,4 In patients with suspected bacterial meningitis, empiric therapy should not be delayed for more than one hour while awaiting diagnostic testing or transfers.4,18,22,23 Although no prospective comparative trials have been performed, observational studies have found that delays in therapy of as little as two to six hours are associated with adverse outcomes.22,23 Factors associated with a delay in antimicrobial therapy include failure to receive antimicrobials before transfer from another facility; performance of head computed tomography before lumbar puncture and antimicrobial administration; and the absence of the cardinal features of fever, neck stiffness, and altered mental status. When administered just before antimicrobial therapy is initiated, concomitant use of dexamethasone for four days has been shown to reduce mortality and improve neurologic outcomes in adults with S. pneumoniae infection.19 It has not been shown to improve outcomes in other patient groups. Studies of patients in the developing world who have a high likelihood of HIV infection have not shown a clear benefit with adjunctive dexamethasone for pyogenic bacterial meningitis.24,25 Fluid management includes treatment for possible dehydration or hyponatremia from the syndrome of inappropriate antidiuretic hormone.

After the results of the Gram stain, culture, and susceptibility tests are available, specific therapy targeting the pathogen should be administered (Table 5 4,11,16,18,26,27). Blood cultures drawn before antimicrobial administration are positive in 61 to 66 percent of patients.5,7 Initiation of antimicrobials before lumbar puncture decreases the yield of CSF culture, the likelihood of a low CSF glucose level, and the degree of elevation of CSF protein; however, it does not markedly influence the results of CSF Gram stain, which is positive in 60 to 70 percent of patients.26,28

Table 5.

Pathogen-Specific Therapy for Common Causes of Bacterial Meningitis

Pathogen* Recommended therapy Adult dosage (intravenous) Days of therapy Alternative therapy

Streptococcus pneumoniae

10 to 14

Meropenem (Merrem), moxifloxacin (Avelox), or chloramphenicol

Penicillin MIC: < 0.1 mcg per mL

Penicillin

4 million units every four hours

Penicillin MIC: 0.1 to 1 mcg per mL

Ceftriaxone† (Rocephin)

2 g every 12 hours

Penicillin MIC: ≥ 2 mcg per mL

Vancomycin plus

15 to 22.5 mg per kg every 12 hours

Ceftriaxone†

2 g every 12 hours

Ceftriaxone MIC: ≥ 1 mcg per mL

Vancomycin plus

15 to 22.5 mg per kg every 12 hours

Ceftriaxone†‡

2 g every 12 hours

Neisseria meningitidis

Ceftriaxone†

2 g every 12 hours

Five to seven

Chloramphenicol, meropenem, or moxifloxacin

Haemophilus influenzae

Ceftriaxone†

2 g every 12 hours

Seven to 10

Chloramphenicol or moxifloxacin

Streptococcus agalactiae (group B streptococcus)

Ampicillin plus Gentamicin

Usually in children

14 to 21

Vancomycin or cefotaxime (Claforan)

Listeria monocytogenes

Ampicillin with or without

2 g every four hours

21

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

Gentamicin§

1 to 2 mg per kg every eight hours

Enterobacteriaceae

Ceftriaxone, ceftazidime (Fortaz), or cefepime (Maxipime) with or without Gentamicin

Varies

21 to 28

Ciprofloxacin (Cipro), meropenem, or trimethoprim/sulfamethoxazole

Staphylococci

Seven to 10 days after shunt removal or cerebrospinal fluid sterilization

Daptomycin (Cubicin) or linezolid (Zyvox), consider adding rifampin

Methicillin susceptible

Nafcillin

2 g every four hours

Methicillin resistant

Vancomycin

15 to 22.5 mg per kg every 12 hours


MIC = minimal inhibitory concentration.

*—Listed in order of most likely to least likely.

—Cefotaxime may be used instead.

—Consider adding rifampin. Vancomycin penetration into cerebrospinal fluid may be diminished with concomitant dexamethasone, but adequate levels are achieved with continuous infusion at 60 mg per kg. 27

§—For the first seven to 10 days.

Information from references 4, 11, 16, 18, 26, and 27.

Table 5.   Pathogen-Specific Therapy for Common Causes of Bacterial Meningitis

View Table

Table 5.

Pathogen-Specific Therapy for Common Causes of Bacterial Meningitis

Pathogen* Recommended therapy Adult dosage (intravenous) Days of therapy Alternative therapy

Streptococcus pneumoniae

10 to 14

Meropenem (Merrem), moxifloxacin (Avelox), or chloramphenicol

Penicillin MIC: < 0.1 mcg per mL

Penicillin

4 million units every four hours

Penicillin MIC: 0.1 to 1 mcg per mL

Ceftriaxone† (Rocephin)

2 g every 12 hours

Penicillin MIC: ≥ 2 mcg per mL

Vancomycin plus

15 to 22.5 mg per kg every 12 hours

Ceftriaxone†

2 g every 12 hours

Ceftriaxone MIC: ≥ 1 mcg per mL

Vancomycin plus

15 to 22.5 mg per kg every 12 hours

Ceftriaxone†‡

2 g every 12 hours

Neisseria meningitidis

Ceftriaxone†

2 g every 12 hours

Five to seven

Chloramphenicol, meropenem, or moxifloxacin

Haemophilus influenzae

Ceftriaxone†

2 g every 12 hours

Seven to 10

Chloramphenicol or moxifloxacin

Streptococcus agalactiae (group B streptococcus)

Ampicillin plus Gentamicin

Usually in children

14 to 21

Vancomycin or cefotaxime (Claforan)

Listeria monocytogenes

Ampicillin with or without

2 g every four hours

21

Trimethoprim/sulfamethoxazole (Bactrim, Septra)

Gentamicin§

1 to 2 mg per kg every eight hours

Enterobacteriaceae

Ceftriaxone, ceftazidime (Fortaz), or cefepime (Maxipime) with or without Gentamicin

Varies

21 to 28

Ciprofloxacin (Cipro), meropenem, or trimethoprim/sulfamethoxazole

Staphylococci

Seven to 10 days after shunt removal or cerebrospinal fluid sterilization

Daptomycin (Cubicin) or linezolid (Zyvox), consider adding rifampin

Methicillin susceptible

Nafcillin

2 g every four hours

Methicillin resistant

Vancomycin

15 to 22.5 mg per kg every 12 hours


MIC = minimal inhibitory concentration.

*—Listed in order of most likely to least likely.

—Cefotaxime may be used instead.

—Consider adding rifampin. Vancomycin penetration into cerebrospinal fluid may be diminished with concomitant dexamethasone, but adequate levels are achieved with continuous infusion at 60 mg per kg. 27

§—For the first seven to 10 days.

Information from references 4, 11, 16, 18, 26, and 27.

Polymerase chain reaction testing of CSF is more sensitive than CSF culture, particularly in patients who received previous antimicrobials.29,30 However, antimicrobial susceptibility testing, which is important in the treatment and prevention of meningitis, can be performed only when the organism is grown in culture. In one series in the United States, 28 percent of pneumococci from patients with meningitis were not susceptible to penicillin, 6 percent were not susceptible to chloramphenicol, 17 percent were not susceptible to meropenem (Merrem), and 12 percent were not susceptible to cefotaxime (Claforan).1 Because of this degree of resistance, the administration of empiric therapy with vancomycin and a third-generation cephalosporin (cefotaxime or ceftriaxone [Rocephin]) is recommended until the results of susceptibility tests are known.

Aseptic Meningitis

Enteroviruses are the most common etiologic pathogens in persons with aseptic meningitis and do not require specific antimicrobial therapy. They can be diagnosed by CSF polymerase chain reaction testing,6 which is not always needed, but a positive test may be useful in discontinuing antimicrobials initiated presumptively for bacterial meningitis. If suggested by the patient's sexual or substance use history, it is appropriate to order serum reactive plasma reagin (RPR), CSF Venereal Disease Research Laboratory (VDRL), serum HIV antibody, and serum HIV polymerase chain reaction tests. In acute HIV seroconversion, the serum HIV antibody test may be negative at the time of clinical presentation.

HSV aseptic meningitis is usually a self-limited infection that must be distinguished from HSV encephalitis based on clinical and radiographic features; therapy with acyclovir (Zovirax) can be lifesaving in patients with HSV encephalitis. In contrast with HSV encephalitis, most patients with HSV aseptic meningitis have normal mental status and neurologic function, and do not have enhancement observed on magnetic resonance imaging of the temporal lobe. Both forms of HSV central nervous system disease are diagnosed by CSF HSV polymerase chain reaction testing. Infection with HSV may cause recurrent disease (e.g., Mollaret meningitis). Varicellazoster virus infection may cause aseptic meningitis in the absence of cutaneous manifestations.6 Although it has not been studied in clinical trials, therapy with acyclovir at 10 mg per kg every eight hours is suggested, based on expert opinion. Central nervous system Lyme disease is treated with ceftriaxone for 14 to 28 days, and central nervous system syphilis is treated with intravenous penicillin for 10 to 14 days.

Tuberculous and Cryptococcal Meningitis

A high index of suspicion is needed to diagnose tuberculous meningitis because culture results are often delayed and stains are often negative. Empiric therapy may be lifesaving. Polymerase chain reaction testing may be useful. Initial treatment is a combination of isoniazid (5 mg per kg per day in adults, 10 mg per kg per day in children, up to 300 mg); rifampin (10 mg per kg per day in adults, 10 to 20 mg per kg per day in children, up to 600 mg); pyrazinamide (15 to 30 mg per kg per day, up to 2 g); and ethambutol (15 to 25 mg per kg per day). Streptomycin (20 to 40 mg per kg per day, up to 1 g) should be used in lieu of ethambutol in young children.31 Adding dexamethasone to the treatment regimen improves mortality in patients older than 14 years with tuberculous meningitis.32

Cryptococcal meningitis is the most common fungal meningitis, and usually occurs in patients with altered cellular immunity. Initial treatment includes amphotericin B (0.7 to 1.0 mg per kg per day intravenously) plus flucytosine (Ancobon; 25 mg per kg every six hours orally).33

Prognosis

The mortality rate in adults with bacterial meningitis in developed countries is 21 percent; it is higher in patients with pneumococcal disease than in those with meningococcal disease.7 Neurologic sequelae include hearing loss in 14 percent of patients and hemiparesis in 4 percent.7 Risk factors for adverse outcomes include advanced age, alteration of mental status on admission, bacteremia, and a CSF white blood cell count of less than 1,000 per μL (1.00 × 109 per L).7 The mortality rate in children with bacterial meningitis is 3 percent; the incidence of stroke in children with bacterial meningitis is 3 percent.34

Prevention

Conjugate vaccines for H. influenzae type B and S. pneumoniae initiated in early childhood have been highly effective in reducing the incidence of bacterial meningitis, not only in children but also in adults.1,2 Although the overall incidence of pneumococcal meningitis has declined with the use of the conjugate vaccine, the percentage of meningitis cases caused by nonvaccine serotypes has increased, as did the percentage of isolates that were not susceptible to penicillin and cefotaxime.1 A newer conjugate vaccine for Neisseria meningitidis (active against serogroups A, C, W135, and Y, but not serogroup B) is recommended in all children 11 to 18 years of age; freshmen entering college dormitories; travelers to regions in which meningococcal disease is endemic (e.g., sub-Saharan Africa; Mecca, Saudi Arabia, during the Hajj); and persons with complement component deficiencies.35 Patients with functional or anatomic asplenia should receive the meningococcal, pneumococcal, and H. influenzae vaccines. Patients hospitalized with N. meningitidis infection or meningitis of uncertain etiology require droplet precautions for the first 24 hours of treatment, or until N. meningitidis can be ruled out. Chemoprophylaxis recommendations are listed in Table 6.11,18,36

Table 6.

Chemoprophylaxis for Bacterial Meningitis

Pathogen Indication Antimicrobial agent Dosage Comments

Neisseria meningitidis (postexposure prophylaxis)

Close contact (for more than eight hours) with someone with N. meningitidis infection

Rifampin

Adults: 600 mg every 12 hours for two days

Not fully effective and rare resistant isolates

or

Children one month or older: 10 mg per kg every 12 hours for two days

Contact with oral secretions of someone with N. meningitidis infection

Children younger than one month: 5 mg per kg every 12 hours for two days

Ciprofloxacin (Cipro)

Adults: single dose of 500 mg

Rare resistant isolates

or

Ceftriaxone (Rocephin)

Single intramuscular dose of 250 mg (125 mg if younger than 15 years)

Haemophilus influenzae (postexposure prophylaxis)

Living in a household with one or more unvaccinated or incompletely vaccinated children younger than 48 months

Rifampin

20 mg per kg per day, up to 600 mg per day, for four days

Streptococcus agalactiae (group B streptococcus; women in the intrapartum period)

Previous birth to an infant with invasive S. agalactiae infection

Penicillin G

Initial dose of 5 million units intravenously, then 2.5 to 3 million units every four hours during the intrapartum period

or

Colonization at 35 to 37 weeks' gestation

If allergic to penicillin:

Clindamycin susceptibility must be confirmed by antimicrobial susceptibility test

Bacteriuria during pregnancy

High risk because of fever, amniotic fluid rupture for more than 18 hours, or delivery before 37 weeks' gestation

Cefazolin

2 g followed by 1 g every eight hours

or

Clindamycin (Cleocin)

900 mg every eight hours

or

Vancomycin

15 to 20 mg per kg every 12 hours


Information from references 11, 18, and 36.

Table 6.   Chemoprophylaxis for Bacterial Meningitis

View Table

Table 6.

Chemoprophylaxis for Bacterial Meningitis

Pathogen Indication Antimicrobial agent Dosage Comments

Neisseria meningitidis (postexposure prophylaxis)

Close contact (for more than eight hours) with someone with N. meningitidis infection

Rifampin

Adults: 600 mg every 12 hours for two days

Not fully effective and rare resistant isolates

or

Children one month or older: 10 mg per kg every 12 hours for two days

Contact with oral secretions of someone with N. meningitidis infection

Children younger than one month: 5 mg per kg every 12 hours for two days

Ciprofloxacin (Cipro)

Adults: single dose of 500 mg

Rare resistant isolates

or

Ceftriaxone (Rocephin)

Single intramuscular dose of 250 mg (125 mg if younger than 15 years)

Haemophilus influenzae (postexposure prophylaxis)

Living in a household with one or more unvaccinated or incompletely vaccinated children younger than 48 months

Rifampin

20 mg per kg per day, up to 600 mg per day, for four days

Streptococcus agalactiae (group B streptococcus; women in the intrapartum period)

Previous birth to an infant with invasive S. agalactiae infection

Penicillin G

Initial dose of 5 million units intravenously, then 2.5 to 3 million units every four hours during the intrapartum period

or

Colonization at 35 to 37 weeks' gestation

If allergic to penicillin:

Clindamycin susceptibility must be confirmed by antimicrobial susceptibility test

Bacteriuria during pregnancy

High risk because of fever, amniotic fluid rupture for more than 18 hours, or delivery before 37 weeks' gestation

Cefazolin

2 g followed by 1 g every eight hours

or

Clindamycin (Cleocin)

900 mg every eight hours

or

Vancomycin

15 to 20 mg per kg every 12 hours


Information from references 11, 18, and 36.

The Author

DAVID M. BAMBERGER, MD, is a professor of medicine at the University of Missouri–Kansas City School of Medicine.

Address correspondence to David M. Bamberger, MD, 2411 Holmes St., Kansas City, MO 64108 (e-mail: bambergerd@umkc.edu). Reprints are not available from the author.

Author disclosure: Nothing to disclose.

REFERENCES

1. Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244–256.

2. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. Active Surveillance Team. N Engl J Med. 1997;337(14):970–976.

3. Thigpen MC, Rosenstein N, Whitney CG, et al. Bacterial meningitis in the United States—1998–2003. Paper presented at: 43rd Annual Meeting of the Infectious Diseases Society of America; October 6–9, 2005; San Francisco, CA. Abstract 65.

4. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–1284.

5. Nigrovic LE, Kuppermann N, Macias CG, et al.; Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Clinical prediction rule for identifying children with cerebrospinal fluid pleocytosis at very low risk of bacterial meningitis. JAMA. 2007;297(1):52–60.

6. Kupila L, Vuorinen T, Vainionpää R, Hukkanen V, Marttila RJ, Kotilainen P. Etiology of aseptic meningitis and encephalitis in an adult population. Neurology. 2006;66(1):75–80.

7. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis [published correction appears in N Engl J Med. 2005;352(9):950]. N Engl J Med. 2004;351(18):1849–1859.

8. Attia J, Hatala R, Cook DJ, Wong JG. The rational clinical examination. Does this adult patient have acute meningitis? JAMA. 1999;282(2):175–181.

9. Thomas KE, Hasbun R, Jekel J, Quagliarello VJ. The diagnostic accuracy of Kernig's sign, Brudzinski's sign, and nuchal rigidity in adults with suspected meningitis. Clin Infect Dis. 2002;35(1):46–52.

10. Cabellos C, Verdaguer R, Olmo M, et al. Community-acquired bacterial meningitis in elderly patients: experience over 30 years. Medicine (Baltimore). 2009;88(2):115–119.

11. Sáez-Llorens X, McCracken GH Jr. Bacterial meningitis in children. Lancet. 2003;361(9375):2139–2148.

12. Kaplan SL. Clinical presentations, diagnosis, and prognostic factors of bacterial meningitis. Infect Dis Clin North Am. 1999;13(3):579–594.

13. Straus SE, Thorpe KE, Holroyd-Leduc J. How do I perform a lumbar puncture and analyze the results to diagnose bacterial meningitis? JAMA. 2006;296(16):2012–2022.

14. Bonsu BK, Harper MB. Utility of the peripheral blood white blood cell count for identifying sick young infants who need lumbar puncture. Ann Emerg Med. 2003;41(2):206–214.

15. Ellenby MS, Tegtmeyer K, Lai S, Braner DA. Videos in clinical medicine. Lumbar puncture. N Engl J Med. 2006;355(13):e12.

16. Fitch MT, van de Beek D. Emergency diagnosis and treatment of adult meningitis. Lancet Infect Dis. 2007;7(3):191–200.

17. Hasbun R, Abrahams J, Jekel J, Quagliarello VJ. Computed tomography of the head before lumbar puncture in adults with suspected meningitis. N Engl J Med. 2001;345(24):1727–1733.

18. Chaudhuri A, Martinez-Martin P, Kennedy PG, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults [published correction appears in Eur J Neurol. 2008;15(8):880]. Eur J Neurol. 2008;15(7):649–659.

19. de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. N Engl J Med. 2002;347(20):1549–1556.

20. Bamberger DM, Smith OJ. Haemophilus influenzae meningitis in an adult with initially normal cerebrospinal fluid. South Med J. 1990;83(3):348–349.

21. Dubos F, Martinot A, Gendrel D, Bréart G, Chalumeau M. Clinical decision rules for evaluating meningitis in children. Curr Opin Neurol. 2009;22(3):288–293.

22. Køster-Rasmussen R, Korshin A, Meyer CN. Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect. 2008;57(6):449–454.

23. Proulx N, Fréchette D, Toye B, Chan J, Kravcik S. Delays in the administration of antibiotics are associated with mortality from adult acute bacterial meningitis. QJM. 2005;98(4):291–298.

24. Assiri AM, Alasmari FA, Zimmerman VA, Baddour LM, Erwin PJ, Tleyjeh IM. Corticosteroid administration and outcome of adolescents and adults with acute bacterial meningitis: a meta-analysis. Mayo Clin Proc. 2009;84(5):403–409.

25. Greenwood BM. Corticosteroids for acute bacterial meningitis. N Engl J Med. 2007;357(24):2507–2509.

26. van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. N Engl J Med. 2006;354(1):44–53.

27. Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis. 2007;44(2):250–255.

28. Nigrovic LE, Malley R, Macias CG, et al.; American Academy of Pediatrics, Pediatric Emergency Medicine Collaborative Research Committee. Effect of antibiotic pretreatment on cerebrospinal fluid profiles of children with bacterial meningitis. Pediatrics. 2008;122(4):726–730.

29. Bøving MK, Pedersen LN, Møller JK. Eight-plex PCR and liquid-array detection of bacterial and viral pathogens in cerebrospinal fluid from patients with suspected meningitis. J Clin Microbiol. 2009;47(4):908–913.

30. Chiba N, Murayama SY, Morozumi M, et al. Rapid detection of eight causative pathogens for the diagnosis of bacterial meningitis by realtime PCR. J Infect Chemother. 2009;15(2):92–98.

31. Blumberg HM, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603–662.

32. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–1751.

33. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291–322.

34. Nigrovic LE, Kuppermann N, Malley R; Bacterial Meningitis Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics. Children with bacterial meningitis presenting to the emergency department during the pneumococcal conjugate vaccine era. Acad Emerg Med. 2008;15(6):522–528.

35. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices. Revised recommenations of the Advisory Committee on Immunization Practices to Vaccinate all Persons Aged 11–18 Years with Meningococcal Conjugate Vaccine. MMWR Morb Mortal Wkly Rep. 2007;56(31):794–795.

36. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases. Prevention of perinatal group B streptococcal disease—revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1–36.


Copyright © 2010 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article